Q2 2026 results highlight ongoing losses and cash burn

Disc Medicine (IRON) released second quarter and first half 2026 results on July 30, 2026, giving investors a fresh look at the company’s cash burn and earnings profile.

For the second quarter, Disc Medicine reported a net loss of US$59.53 million compared with US$55.25 million a year earlier. Basic loss per share from continuing operations was US$1.54 compared with US$1.58 a year ago, which points to a slightly smaller per share loss despite the higher total loss.

Across the first six months of 2026, net loss reached US$123.04 million compared with US$89.33 million in the same period of 2025. Basic loss per share from continuing operations for the half was US$3.19 compared with US$2.61 a year earlier.

Disc Medicine’s latest earnings report arrived after a period where the stock has been volatile yet still strong over longer horizons, with a 90 day share price return of 15.08% and a 1 year total shareholder return of 30.57%.

If the current move in Disc Medicine has you thinking about where else growth and risk are shifting in healthcare, this is a good moment to scan 41 healthcare AI stocks

Bulls point to Disc Medicine’s hematology pipeline and recent share price strength. Bears focus on widening losses and ongoing cash burn. Which side does the current valuation appear to support as you weigh the risk and potential reward?

Disc Medicine valuation: DCF points to a steep discount

The SWS DCF model currently estimates a fair value for Disc Medicine of $345.16 per share, compared with the recent close at $77. This suggests the stock is trading at a steep discount if the cash flow forecasts play out as modeled.

The DCF approach projects Disc Medicine’s potential future cash flows and then discounts those back to today’s value. That calculation is sensitive to assumptions about future revenue growth, margins, and the time it could take for a clinical stage biopharmaceutical company with no current revenue to reach commercial scale.

Disc Medicine is still loss making, with reported net income of a loss of $245.89m and meaningful revenue yet to start. That makes a DCF framework a key tool for investors who are weighing the company’s hematology pipeline, the forecast annual revenue growth of 68.1%, and the risk that earnings are forecast to remain in loss territory over at least the next three years.

The model output also sits alongside other valuation checks. Disc Medicine is assessed as trading 77.7% below the internal fair value estimate and is described as good value relative to that DCF result. At the same time, the stock’s P/B ratio of 4.6x screens as higher than the broader US biotechs sector average of 2.4x and lower than the peer group average of 5.4x.

Result: DCF Fair value of $345.16 (UNDERVALUED)

However, Disc Medicine still reports no revenue and ongoing net losses, so any delay or setback across its hematology pipeline could quickly challenge the DCF optimism.

Another view on Disc Medicine’s valuation

While the SWS DCF model points to a steep discount for Disc Medicine, the P/B ratio tells a different story. The stock trades at 4.6x book value, above the US biotechs industry average of 2.4x yet below the peer group average of 5.4x.

This mix suggests that some peers carry richer balance sheet based valuations, while the broader sector trades on more modest terms. For you as an investor, the question is whether Disc Medicine’s pipeline and risk profile justify sitting closer to peer levels or nearer to the cheaper industry average.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Disc Medicine for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The balance of risks and rewards around Disc Medicine will feel different for every investor based on time horizon and risk tolerance. Act promptly, review the figures above in detail, and then weigh both sides of the story with the help of 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Disc Medicine?

If Disc Medicine has sharpened your focus on risk and return trade offs, do not stop here. Broader opportunities could suit your goals even better.

• Spot potential value candidates early and compare them against Disc Medicine by running through 55 high quality undervalued stocks before sentiment shifts.
• Build a steadier income focused watchlist and see how those payouts stack up next to growth stories like Disc Medicine using 9 dividend fortresses.
• Strengthen your core holdings with companies that carry sturdier finances by screening the market through solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.